Translations:SGLT2 inhibitor/6/en

Two reviews have concluded that SGLT2 inhibitors benefit patients with atherosclerotic major adverse cardiovascular events (MACE). One of those studies defined MACE as the composite of myocardial infarction, stroke, or cardiovascular death.